Market revenue in 2021 | USD 2,657.0 million |
Market revenue in 2028 | USD 8,866.2 million |
Growth rate | 18.8% (CAGR from 2021 to 2028) |
Largest segment | Commercialized |
Fastest growing segment | Research |
Historical data covered | 2018 - 2020 |
Base year for estimation | 2021 |
Forecast period covered | 2022 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Research, Commercialized |
Key market players worldwide | Novartis AG ADR, Merck KGaA, Gilead Sciences Inc, Adaptimmune Therapeutics PLC ADR, Bluebird bio Inc, Sorrento Therapeutics Inc, Fate Therapeutics Inc, Pfizer Inc, Amgen Inc, Bristol-Myers Squibb Co |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to t-cell therapy market will help companies and investors design strategic landscapes.
Commercialized was the largest segment with a revenue share of 59.28% in 2021. Horizon Databook has segmented the North America t-cell therapy market based on research, commercialized covering the revenue growth of each sub-segment from 2018 to 2028.
North America currently holds the largest share of global T-cell therapy market and is anticipated to continue its dominance over the forecast period. Increasing usage of Adoptive T-Cell Therapy (ACT) for treatment of cancers is one of the major factors propelling market growth. The approval of two CAR T-cell therapies in 2017 for the treatment of Acute Lymphoblastic Leukemia (ALL) and advanced lymphomas has led to an increase in their adoption in the U.S. and Canada.
Presence of major manufacturers and economic development are some of the major factors propelling the growth of North America T-cell therapy market. Most manufacturers are focusing on development, commercialization, and distribution of advanced products to cater to the growing cancer patient pool in the region.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America t-cell therapy market , including forecasts for subscribers. This continent databook contains high-level insights into North America t-cell therapy market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account